- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Rossari Biotech Limited's Board has approved the audited financial results for the quarter and financial year ending March 31, 2025, reporting a profit after tax of ₹1,363.78 crore, up from ₹1,306.89 crore year-on-year. The company declared a final dividend of ₹0.50 per share. Additionally, M/s. Shah Patel & Associates has been appointed as the Secretarial Auditor for five years, and the Board approved granting 834,250 stock options under the Employee Stock Option Plan. The company is also moving forward with a capacity expansion project requiring an investment of ₹95 crore. This growth initiative aligns with market demand, aiming to bolster competitiveness in the sector. Investor sentiment may lean positively due to the solid financial performance and proactive steps towards expansion.